Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High
Charles River Laboratories International Inc. (NYSE: CRL ) stock traded higher Wednesday after the contract research organization raised its full-year 2026 financial guidance following second-quarter results that exceeded Wall Street expectations. The company increased its fiscal 2026 adjusted earnings outlook to $11.1